SG11201807965YA - Combinations of lsd1 inhibitors for use in the treatment of solid tumors - Google Patents
Combinations of lsd1 inhibitors for use in the treatment of solid tumorsInfo
- Publication number
- SG11201807965YA SG11201807965YA SG11201807965YA SG11201807965YA SG11201807965YA SG 11201807965Y A SG11201807965Y A SG 11201807965YA SG 11201807965Y A SG11201807965Y A SG 11201807965YA SG 11201807965Y A SG11201807965Y A SG 11201807965YA SG 11201807965Y A SG11201807965Y A SG 11201807965YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- roche
- combinations
- tcrc
- alexandria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111 01E3 100 111110101110 11n III 11 International Bureau 0.. .... .. (10) International Publication Number ..... ..or::,„, (43) International Publication Date WO 2017/157825 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: Life Science, New York, NY 10016 (US). MAES, A61K 31/12 (2006.01) A61K 31/475 (2006.01) Tamara; c/o Oryzon Genomics S.A., C. Sant Ferran 74, A61K 31/135 (2006.01) A61K 31/495 (2006.01) 08940 Cornelia de Llobregat (ES). LUNARDI, Serena; A61K 31/19 (2006.01) A61K 31/519 (2006.01) c/o Oryzon Genomics S.A., C. Sant Ferran 74, 08940 Cor- A61K 31/282 (2006.01) A61K 31/555 (2006.01) nella de Llobregat (ES). A61K 31/337 (2006.01) A61K 31/704 (2006.01) A61K 31/4045 (2006.01) A61K 31/7068 (2006.01) (74) Agent: MUELLER-AFRAZ, Simona; Grenzacherstrasse A61K 31/4745 (2006.01) A61P 35/00 (2006.01) 124, 4070 Basel (CH). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2017/055784 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 13 March 2017 (13.03.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/308,529 15 March 2016 (15.03.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant (for all designated States except US): F. HOFF- ZA, ZM, ZW. MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse (84) Designated States (unless otherwise indicated, for every 124, 4070 Basel (CH). kind of regional protection available): ARIPO (BW, GH, Applicant (for US only): HOFFMANN-LA ROCHE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, INC. [US/US]; Overlook at Great Notch, 150 Clove Road TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 8th Floor, Suite 8 - Legal Department, Little Falls, NJ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 07424 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) = (72) Inventors: DEMARIO, Mark; c/o Roche TCRC, Inc. East SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 29th Street, Alexandria Center for Life Science, New York, GW, KM, ML, MR, NE, SN, TD, TG). = = NY 10016 (US). PIERCEALL, William; c/o Roche TCRC, Inc. East 29th Street, Alexandria Center for Life Published: — — Science, New York, NY 10016 (US). MACK, Fiona; c/o — with international search report (Art. 21(3)) Roche TCRC, Inc. East 29th Street, Alexandria Center for = = = = = = = Il kin ei cc IN kin ,-1 IN ,-1 © (54) Title: COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS ei 0 (57) : The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharma- ceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308529P | 2016-03-15 | 2016-03-15 | |
PCT/EP2017/055784 WO2017157825A1 (en) | 2016-03-15 | 2017-03-13 | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807965YA true SG11201807965YA (en) | 2018-10-30 |
Family
ID=58266657
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807965YA SG11201807965YA (en) | 2016-03-15 | 2017-03-13 | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
SG10201913331VA SG10201913331VA (en) | 2016-03-15 | 2017-03-13 | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913331VA SG10201913331VA (en) | 2016-03-15 | 2017-03-13 | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
Country Status (14)
Country | Link |
---|---|
US (2) | US10265279B2 (en) |
EP (1) | EP3429571A1 (en) |
JP (2) | JP7158023B2 (en) |
KR (2) | KR102511024B1 (en) |
CN (1) | CN109195593A (en) |
AR (1) | AR107871A1 (en) |
AU (2) | AU2017233898B2 (en) |
BR (1) | BR112018068565A2 (en) |
CA (1) | CA3017411A1 (en) |
EA (1) | EA201892075A1 (en) |
IL (1) | IL261721B (en) |
MX (2) | MX2018011102A (en) |
SG (2) | SG11201807965YA (en) |
WO (1) | WO2017157825A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2681211C2 (en) | 2011-10-20 | 2019-03-05 | Оризон Дженомикс С.А. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
WO2017157813A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
PL3307267T3 (en) | 2016-06-10 | 2019-10-31 | Oryzon Genomics Sa | Multiple sclerosis treatment |
WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy |
US11597933B2 (en) | 2017-11-29 | 2023-03-07 | The Trustees Of Columbia University In The City Of New York | Combination therapy of lymphoma |
MX2020011534A (en) * | 2018-05-04 | 2020-11-24 | Oryzon Genomics Sa | Stable pharmaceutical formulation. |
AU2019266150A1 (en) * | 2018-05-06 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
CN109265462B (en) * | 2018-10-31 | 2020-06-02 | 郑州大学 | Pyrimido 1,2, 4-triazole compound and preparation method and application thereof |
JP2022546908A (en) * | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Biomarkers and methods for personalized treatment of small cell lung cancer using KDM1A inhibitors |
CN110863047B (en) * | 2019-11-15 | 2022-09-13 | 西安交通大学医学院第一附属医院 | Application of human CCDC154 gene and related product |
WO2021154878A1 (en) * | 2020-01-28 | 2021-08-05 | PAIGE.AI, Inc. | Systems and methods for processing electronic images for biomarker localization |
CN115551501B (en) * | 2020-05-12 | 2024-03-22 | 石药集团中奇制药技术(石家庄)有限公司 | Application of LSD1 inhibitor |
WO2023067058A1 (en) | 2021-10-20 | 2023-04-27 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
GB202115017D0 (en) | 2021-10-20 | 2021-12-01 | Univ London Queen Mary | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2802005A (en) | 1957-08-06 | S-eluorourace | ||
US2331725A (en) | 1941-01-31 | 1943-10-12 | Lederle Lab Inc | Preparation of 2-methyl-1,4-naphthoquinone |
US3205220A (en) | 1961-10-26 | 1965-09-07 | Lilly Co Eli | Leurosidine and leurocristine and their production |
CH514578A (en) | 1968-02-27 | 1971-10-31 | Sandoz Ag | Process for the production of glucosides |
GB1457632A (en) | 1974-03-22 | 1976-12-08 | Farmaceutici Italia | Adriamycins |
DD159877A1 (en) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | PROCESS FOR PREPARING 4- [1-METHYL-5-BIS (2-CHLOROETHYL) AMINO-BENZIMIDAZOLYL-2] BUTTERIC ACID |
OA07174A (en) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | New imidazotetrazionones, their preparation and medicines containing them. |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
ES8604088A1 (en) | 1985-06-14 | 1986-01-16 | Espanola Farma Therapeut | Platinum complex with cyclobutane di:carboxylic acid |
FR2601676B1 (en) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL |
FR2601675B1 (en) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
IL96531A (en) | 1989-12-11 | 1995-08-31 | Univ Princeton | N-(disubstituted-1h-pyrrolo [2,3-d] pyrimidin-3-ylacyl)-glutamic acid derivatives their preparation and pharmaceutical compositions containing them |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
IL117684A (en) | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and process for the manufacture of camptothesin derivatives (cpt-11) and related compounds |
JP3354090B2 (en) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | Differentiation inducer |
US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
RS49779B (en) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
EP1644363B1 (en) | 2003-05-30 | 2012-02-22 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
CA2560580C (en) | 2004-03-23 | 2008-12-23 | Pfizer Products Inc. | Imidazole compounds for inhibition of a.beta.-peptide production and for modulation of the notch signaling pathway |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
BRPI0514504A (en) | 2004-08-20 | 2008-06-10 | Univ Michigan | small inhibitory molecules of the anti-apoptotic bcl-2 family members and their uses |
JP5143558B2 (en) | 2004-09-02 | 2013-02-13 | ジェネンテック,インコーポレイティド | Pyridyl inhibitors of hedgehog signaling |
CA2591717A1 (en) | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
DK1704859T3 (en) | 2005-02-18 | 2010-11-22 | Universitaetsklinikum Freiburg | Control of androgen receptor-dependent gene expression by inhibiting the amine oxidase activity of lysine-specific demethylase (LSD1) |
EP1869020B1 (en) | 2005-03-29 | 2010-12-01 | ICOS Corporation | Heteroaryl urea derivatives useful for inhibiting chk1 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
EP1940773B1 (en) | 2005-08-10 | 2015-03-18 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
NL2000613C2 (en) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazole pyrazine derivatives. |
CL2007003244A1 (en) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
US20110092601A1 (en) | 2007-04-13 | 2011-04-21 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
CN101868446A (en) | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | The synthetic method of some hydroxamic acid compound |
EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
BR122020009045B1 (en) | 2008-09-17 | 2022-08-02 | Sun Pharma Global Fze | USE OF N-[6-CIS-2,6-DIMETHYLMORPHOLIN-4-YL]PYRIDINE-3-YL]-2-METHYL-4'-(TRIFLUORMETOXY)[1,1'-BIPHENYL]-3-CARBOXAMIDE SALTS IN THE TREATMENT OF CARCINOMA AND OTHER TUMORS |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
KR20170037683A (en) | 2009-05-26 | 2017-04-04 | 애브비 아일랜드 언리미티드 컴퍼니 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
WO2010143582A1 (en) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | Phenylcyclopropylamine derivatives and lsd1 inhibitors |
AR077014A1 (en) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER |
US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
HUE030679T2 (en) | 2010-01-22 | 2017-05-29 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
US20130197088A1 (en) | 2010-03-12 | 2013-08-01 | Robert A. Casero, JR. | Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO) |
CN102947265B (en) | 2010-04-19 | 2015-07-29 | 奥瑞泽恩基因组学股份有限公司 | Methionin specific demethylase-1 inhibitor and application thereof |
ES2564352T3 (en) | 2010-04-20 | 2016-03-22 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as histone demethylase inhibitors LSD1 and / or LSD2 |
JP5864545B2 (en) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Indole |
ES2534804T3 (en) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
CN103119160B (en) | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | For regulating compositions and the method for metabolism |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
CN103124724B (en) | 2010-07-29 | 2015-05-20 | 奥瑞泽恩基因组学股份有限公司 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
BR112013013659B8 (en) | 2010-12-03 | 2024-02-27 | Epizyme Inc | Epigenetic enzyme modulating compounds, pharmaceutical composition comprising said compounds and uses of said pharmaceutical composition for treating cancer, hematological cancer or leukemia |
EP2712316A1 (en) | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
US20140066410A1 (en) | 2011-02-23 | 2014-03-06 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TWI530489B (en) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
CA2831143C (en) | 2011-03-25 | 2019-05-21 | Glaxosmithkline Intellectual Property Development Limited | Cyclopropylamines as lsd1 inhibitors |
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
EP2750671A2 (en) | 2011-05-19 | 2014-07-09 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
AR087107A1 (en) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY |
KR20140052018A (en) | 2011-08-09 | 2014-05-02 | 다케다 야쿠힌 고교 가부시키가이샤 | Cyclopropaneamine compound |
SI2744330T1 (en) | 2011-08-15 | 2020-11-30 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
EP4074695A1 (en) | 2011-10-20 | 2022-10-19 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
RU2681211C2 (en) | 2011-10-20 | 2019-03-05 | Оризон Дженомикс С.А. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9828344B2 (en) | 2012-06-01 | 2017-11-28 | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI) | Inhibitors of the notch signaling pathway and secretion for use in medicine |
JP6325449B2 (en) | 2012-10-12 | 2018-05-16 | 武田薬品工業株式会社 | Cyclopropanamine compounds and uses thereof |
JP6238908B2 (en) | 2012-11-28 | 2017-11-29 | 京都府公立大学法人 | LSD1 selective inhibitor having lysine structure |
US9144555B2 (en) | 2012-11-30 | 2015-09-29 | Darlene E. McCord | Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
WO2014134583A2 (en) | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
AU2014236348B2 (en) | 2013-03-14 | 2018-05-10 | Epizyme, Inc. | Combination therapy for treating cancer |
EP3003301B1 (en) | 2013-05-30 | 2021-02-24 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
SG11201510376QA (en) | 2013-06-19 | 2016-01-28 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
EP2829284A1 (en) | 2013-07-22 | 2015-01-28 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
CN105592888A (en) | 2013-08-06 | 2016-05-18 | 伊美格生物科学公司 | Kdm1a inhibitors for the treatment of disease |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
CN105873592B (en) | 2013-12-06 | 2023-01-31 | Epizyme股份有限公司 | Combination therapy for the treatment of cancer |
EP4257591A3 (en) | 2013-12-11 | 2023-11-22 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
US10118903B2 (en) | 2014-02-07 | 2018-11-06 | Musc Foundation For Research Development | Aminotriazole-based KDM1A inhibitors as epigenetic modulators |
HUE045725T2 (en) | 2014-02-13 | 2020-01-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
LT3105218T (en) | 2014-02-13 | 2019-12-10 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
AU2015226881A1 (en) * | 2014-03-07 | 2016-09-29 | Intonation Research Laboratories | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs) |
CN106459024B (en) | 2014-04-11 | 2019-11-05 | 武田药品工业株式会社 | Cyclopropyl amine compounds and application thereof |
TWI676620B (en) | 2014-05-01 | 2019-11-11 | 美商賽基昆堤塞爾研發公司 | Inhibitors of lysine specific demethylase-1 |
EP3148974B1 (en) | 2014-05-30 | 2018-09-26 | Istituto Europeo di Oncologia S.r.l. | Cyclopropylamine compounds as histone demethylase inhibitors |
HUE050564T2 (en) | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
US9902719B2 (en) | 2014-07-03 | 2018-02-27 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2016004105A1 (en) | 2014-07-03 | 2016-01-07 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
JP2017527547A (en) * | 2014-08-13 | 2017-09-21 | エピザイム,インコーポレイティド | Combination therapy to treat cancer |
EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
SG11201701683XA (en) | 2014-09-05 | 2017-04-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
CN107438593B (en) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | Therapeutic compounds and uses thereof |
KR102626978B1 (en) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | Kdm1a inhibitors for the treatment of disease |
CN106146361A (en) | 2015-03-16 | 2016-11-23 | 四川大学 | Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use |
MA51438A (en) | 2015-04-03 | 2021-04-14 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS LSD1 INHIBITORS |
CN106045862B (en) | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | Cyclopropyl amine spiral shell (miscellaneous) cycle compound, its pharmaceutical composition and application |
EP3286172B1 (en) | 2015-04-23 | 2019-06-12 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
SG10201911989SA (en) | 2015-06-12 | 2020-02-27 | Oryzon Genomics Sa | Biomarkers associated with lsd1 inhibitors and uses thereof |
US20170001970A1 (en) | 2015-07-02 | 2017-01-05 | University Of Utah Research Foundation | Substituted benzohydrazide analogs as histone demethylase inhibitors |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
MX2018001706A (en) | 2015-08-12 | 2018-09-06 | Incyte Corp | Salts of an lsd1 inhibitor. |
CN105233292B (en) * | 2015-10-19 | 2018-03-13 | 中国科学院北京基因组研究所 | The combined radiotherapies of ORY 1001 and chemotherapy are used for the purposes for treating people's triple negative breast cancer |
CN105541806A (en) | 2015-12-25 | 2016-05-04 | 中国药科大学 | Barbiturate compound, preparing method and application thereof |
CN105924362B (en) | 2016-02-05 | 2018-08-17 | 上海龙翔生物医药开发有限公司 | Aromatic rings allylamine compound, its pharmaceutically acceptable salt, Its Preparation Method And Use |
SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
WO2017157813A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
JP2019512546A (en) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Methods for determining KDM1A target association, and chemical probes useful therefor |
CN106045881B (en) | 2016-05-26 | 2017-10-31 | 新乡医学院 | Resveratrol derivative, its preparation method and the application as LSD1 inhibitor |
-
2017
- 2017-03-13 SG SG11201807965YA patent/SG11201807965YA/en unknown
- 2017-03-13 JP JP2018548076A patent/JP7158023B2/en active Active
- 2017-03-13 CN CN201780029779.1A patent/CN109195593A/en active Pending
- 2017-03-13 BR BR112018068565-8A patent/BR112018068565A2/en active Search and Examination
- 2017-03-13 KR KR1020187029530A patent/KR102511024B1/en active IP Right Grant
- 2017-03-13 MX MX2018011102A patent/MX2018011102A/en unknown
- 2017-03-13 AU AU2017233898A patent/AU2017233898B2/en active Active
- 2017-03-13 SG SG10201913331VA patent/SG10201913331VA/en unknown
- 2017-03-13 EP EP17710261.3A patent/EP3429571A1/en active Pending
- 2017-03-13 KR KR1020237008475A patent/KR20230042756A/en not_active Application Discontinuation
- 2017-03-13 CA CA3017411A patent/CA3017411A1/en active Pending
- 2017-03-13 WO PCT/EP2017/055784 patent/WO2017157825A1/en active Application Filing
- 2017-03-13 IL IL261721A patent/IL261721B/en unknown
- 2017-03-13 EA EA201892075A patent/EA201892075A1/en unknown
- 2017-03-14 US US15/458,640 patent/US10265279B2/en active Active
- 2017-03-14 AR ARP170100628A patent/AR107871A1/en unknown
-
2018
- 2018-09-13 MX MX2021004639A patent/MX2021004639A/en unknown
-
2022
- 2022-05-04 US US17/661,971 patent/US20220378722A1/en active Pending
- 2022-10-03 JP JP2022159223A patent/JP2023011569A/en active Pending
-
2023
- 2023-03-14 AU AU2023201580A patent/AU2023201580A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017157825A1 (en) | 2017-09-21 |
BR112018068565A2 (en) | 2019-02-12 |
KR20230042756A (en) | 2023-03-29 |
AU2017233898A1 (en) | 2018-11-01 |
EP3429571A1 (en) | 2019-01-23 |
KR102511024B1 (en) | 2023-03-16 |
JP2019508440A (en) | 2019-03-28 |
CA3017411A1 (en) | 2017-09-21 |
MX2018011102A (en) | 2019-01-10 |
KR20180118229A (en) | 2018-10-30 |
US20220378722A1 (en) | 2022-12-01 |
IL261721B (en) | 2022-07-01 |
SG10201913331VA (en) | 2020-03-30 |
US10265279B2 (en) | 2019-04-23 |
IL261721A (en) | 2018-10-31 |
CN109195593A (en) | 2019-01-11 |
JP2023011569A (en) | 2023-01-24 |
JP7158023B2 (en) | 2022-10-21 |
AR107871A1 (en) | 2018-06-13 |
AU2017233898B2 (en) | 2022-12-15 |
EA201892075A1 (en) | 2019-04-30 |
AU2023201580A1 (en) | 2023-04-13 |
US20170281567A1 (en) | 2017-10-05 |
MX2021004639A (en) | 2022-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201810268YA (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
SG11201810793XA (en) | Pharmaceutical combinations | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof |